US Edition
Engineered CD40 antibody shrinks tumors and induces remission
An engineered CD40 antibody induced tumor shrinkage in half of 12 metastatic cancer patients with two achieving complete remission and no serious side effects, researchers said.
- Researchers published results from a 2025 phase 1 clinical trial injecting the drug 2141-V11 into tumors of 12 metastatic cancer patients.
- The trial followed earlier 2018 lab work by Ravetch's team that engineered an enhanced CD40 antibody to boost efficacy and limit severe side effects.
- Patients included those with melanoma, renal cell carcinoma, and breast cancer, and tumor shrinkage occurred systemically, not just at injection sites.
- Six patients saw tumor reduction while two had complete remission, with immune cells forming lymph node-like structures inside tumors, showing systemic antitumor immunity.
- The trial's unexpected systemic response and mild toxicity suggest 2141-V11 could expand treatment options and inspire ongoing trials on other aggressive cancers.
13 Articles
13 Articles
CD40 agonist antibodies have shown their efficacy without adverse effects in a clinical trial of 12 patients with metastatic cancer: six saw their tumors shrink, including two in whom they completely disappeared.
The medicine, a new version of the promising CD40 agonist antibodies, is injected directly into the tumor. It has been tested in 12 patients with various types of metastatic cancer.
CD40 agonist antibodies are a very promising class of cancer drugs but, although in animal models they have managed to activate the immune system and kill cancer cells, in patients they have a limited impact and cause serious side effects.The entry A clinical trial with twelve patients reduces or eliminates aggressive cancers in six of them was first published in Digital Process.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
